Abstract
Introduction: Discordance between gastrointestinal (GI) symptoms and endoscopic inflammation in patients with ulcerative colitis (UC) is known. However, the correlations between symptoms and endoscopic and histologic (endo-histologic) mucosal healing and remains unknown. Methods: We performed a secondary analysis of prospectively collected clinical, endoscopic, and histologic data on 254 colonoscopies from 179 unique adults at a tertiary referral center from 2014 to 2021. Spearman’s rank was used to assess the correlation between patient reported outcomes and objective assessments of disease activity, as measured by validated instruments: Two-item patient-reported outcome measure (PRO-2) for stool frequency and rectal bleeding, the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) for endoscopic inflammation, and the Geboes score for histologic inflammation. The predictive value of objective assessments of inflammation and clinical symptoms was described using sensitivity, specificity, and positive/negative predictive value. Results: One-quarter (28%, 72/254) of cases were in endo-histologic remission; of these, 25% (18/72) report GI symptoms (22% diarrhea; 6% rectal bleeding). Endo-histologically active disease had higher sensitivity (95% rectal bleeding; 87% diarrhea) and negative predictive value (94% rectal bleeding, 78% diarrhea) for clinically active disease compared to active disease on endoscopic (77%) or histologic assessment only (80%). The specificity of endo/histologic inflammation for GI symptoms was < 65%. PRO-2 was positively correlated with endoscopic disease activity (Spearman’s rank 0.57, 95% CI 0.54–0.60, p < 0.0001) and histologic disease activity (Spearman’s rank 0.49, 0.45–0.53, p < 0.0001). Conclusion: One-quarter of patients with ulcerative colitis in endo-histologic (deep) remission have gastrointestinal symptoms, more commonly with diarrhea than rectal bleeding. Endo-histologic inflammation has high sensitivity (≥ 87%) for diarrhea/rectal bleeding.
Original language | English (US) |
---|---|
Pages (from-to) | 3254-3258 |
Number of pages | 5 |
Journal | Digestive diseases and sciences |
Volume | 68 |
Issue number | 8 |
DOIs | |
State | Published - Aug 2023 |
Funding
This study is funded by the AGA Research Foundation’s AGA-Bristol Myers Squibb Pilot Research Award in Inflammatory Bowel Disease Health Disparities (AGA2022-21–03; Dr. Tse). Dr. Singh is supported by NIDDK K23DK117058 and R03DK129631, Litwin Pioneers in IBD grant, and PCORI Contract CER-2020C3-21024. Dr. Boland is supported by NIH K23 DK123406 and NIH P30 DK120515. Dr. Dulai is supported by a Digestive Diseases Research Center grant NIH DK12051.
Keywords
- Clinical endpoints
- Endoscopic remission
- Mucosal healing
- Outcomes
- Patient-reported
ASJC Scopus subject areas
- Physiology
- Gastroenterology